From inflammatory initiation to fibrotic remodeling: mechanisms and precision therapeutic strategies in otorhinolaryngologic involvement of IgG4-related disease - Scorecard - MDSpire
Advertisement
From inflammatory initiation to fibrotic remodeling: mechanisms and precision therapeutic strategies in otorhinolaryngologic involvement of IgG4-related disease
Clinical Scorecard: Mechanisms and Targeted Treatment Approaches for Inflammatory Onset and Fibrotic Changes in IgG4-Related Disease Affecting Otorhinolaryngology
At a Glance
Category
Detail
Condition
IgG4-related disease (IgG4-RD)
Key Mechanisms
Involves clonally expanded CD4+ cytotoxic T lymphocytes, activated follicular helper T cells, and a Th2-skewed cytokine environment promoting IgG4 class-switch recombination.
Target Population
Middle-aged to elderly males, with a peak incidence in the sixth and seventh decades of life; higher female proportion in Mikulicz phenotype.
Care Setting
Otorhinolaryngology
Key Highlights
IgG4-RD is a systemic fibroinflammatory disorder with broad organ involvement.
Glucocorticoids are the standard first-line treatment but have high relapse rates.
Rituximab shows efficacy in refractory and relapsing disease.
Inebilizumab has demonstrated significant benefit in clinical trials.
Dupilumab shows potential but requires further validation.
Guideline-Based Recommendations
Diagnosis
Serum IgG4 concentration exceeding 135 mg/dL is a recognized feature.
Management
First-line treatment includes glucocorticoids; consider rituximab for refractory cases.
Monitoring & Follow-up
Monitor serum IL-5 and CCL17 as potential markers of disease activity.
Risks
Progressive fibrotic remodeling can lead to irreversible organ dysfunction.
Patient & Prescribing Data
Predominantly middle-aged to elderly males, with variations in female representation based on organ involvement.
Individualized treatment approaches based on organ-specific immunopathological differences are suggested.
Clinical Best Practices
Utilize biomarkers such as serum IL-5 and CCL17 for monitoring disease activity.
Consider organ-specific characteristics when developing treatment plans.
